FIELD: biotechnology.
SUBSTANCE: proposed are a new antibody specifically binding to the tumour immunosuppressor TIGIT (T-cell immunoreceptor with an immunoglobulin domain and an immunoreceptor tyrosine-based inhibition motif [ITIM]), or its antigen-binding fragment, nucleic acid encoding this antibody, vector and host cell containing such nucleic acid, method for producing such antibody or its antigen-binding fragment, pharmaceutical composition containing this antibody or its antigen-binding fragment as an active ingredient.
EFFECT: group of inventions is applied for effective treatment of cancer or tumours.
17 cl, 4 dwg, 9 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODY-DRUG CONJUGATES INCLUDING ANTIBODY AGAINST HUMAN DLK1 AND THEIR USE | 2020 |
|
RU2801630C2 |
| ANTIBODIES AGAINST VISTA AND APPLICATION THEREOF | 2018 |
|
RU2750723C1 |
| ANTIBODY AGAINST ANG2 AND ITS USE | 2020 |
|
RU2788088C1 |
| ANTIBODY AGAINST TIE-2 AND ITS USE | 2020 |
|
RU2795455C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804772C2 |
| THIOREDOXIN-1 EPITOPE AND MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO IT | 2018 |
|
RU2797266C2 |
| MONOCLONAL ANTIBODY SPECIFICALLY BINDING TO THE THIOREDOXIN-1 EPITOPE, ITS PREPARATION AND APPLICATION | 2018 |
|
RU2790687C2 |
| THIOREDOXIN-1 EPITOPE BINDING SPECIFICALLY TO MONOCLONAL ANTIBODY | 2018 |
|
RU2804126C2 |
